Denali Therapeutics - DNLI Stock Forecast, Price & News

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Wedbush cut their target price on Denali Therapeutics from $62.00 to $48.00 in a research note on Friday, May 6th. Berenberg Bank started coverage on Denali Therapeutics in a research note on Thursday, June 23rd. They issued a "buy" rating and a $39.00 target price on the stock. Finally, The Goldman Sachs Group dropped their price objective on Denali Therapeutics from $99.00 to $82.00 and set a "buy" rating on the stock in a research report on Tuesday, May 24th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $76.29.

Denali Therapeutics Trading Down 1.0 %

DNLI Stock traded down $0.37 during trading on Friday, reaching $38.11. The stock had a trading volume of 718,434 shares, compared to its average volume of 599,497. Denali Therapeutics has a 52 week low of $20.24 and a 52 week high of $56.80. The stock's 50 day moving average is $31.13 and its two-hundred day moving average is $30.35. The firm has a market cap of $4.70 billion, a PE ratio of -16.59 and a beta of 1.66.

Denali Therapeutics (NASDAQ:DNLI - Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.07. Denali Therapeutics had a negative return on equity of 30.06% and a negative net margin of 252.50%. The company had revenue of $52.50 million for the quarter, compared to the consensus estimate of $44.66 million. During the same quarter in the prior year, the company earned ($0.50) earnings per share. Denali Therapeutics's revenue was up 129.3% on a year-over-year basis. On average, research analysts anticipate that Denali Therapeutics will post -2.69 EPS for the current year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Marc Tessier-Lavigne sold 20,000 shares of the stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $35.61, for a total value of $712,200.00. Following the transaction, the director now owns 1,950,356 shares of the company's stock, valued at $69,452,177.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 12.70% of the stock is owned by corporate insiders.